Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien, … , Christos Sotiriou, Karen Willard-Gallo
Chunyan Gu-Trantien, … , Christos Sotiriou, Karen Willard-Gallo
Published June 17, 2013
Citation Information: J Clin Invest. 2013;123(7):2873-2892. https://doi.org/10.1172/JCI67428.
View: Text | PDF
Research Article Oncology

CD4+ follicular helper T cell infiltration predicts breast cancer survival

  • Text
  • PDF
Abstract

CD4+ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce an image of CD4+ T cells infiltrating breast tumors using limited ex vivo manipulation to better understand the in vivo differences associated with patient prognosis. We performed comprehensive molecular profiling of infiltrating CD4+ T cells isolated from untreated invasive primary tumors and found that the infiltrating T cell subpopulations included follicular helper T (Tfh) cells, which have not previously been found in solid tumors, as well as Th1, Th2, and Th17 effector memory cells and Tregs. T cell signaling pathway alterations included a mixture of activation and suppression characterized by restricted cytokine/chemokine production, which inversely paralleled lymphoid infiltration levels and could be reproduced in activated donor CD4+ T cells treated with primary tumor supernatant. A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4+ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers. An 8-gene Tfh signature, signifying organized antitumor immunity, robustly predicted survival or preoperative response to chemotherapy. Our identification of CD4+ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.

Authors

Chunyan Gu-Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind, Marie Ravoet, Hélène Le Buanec, Catherine Sibille, Germain Manfouo-Foutsop, Isabelle Veys, Benjamin Haibe-Kains, Sandeep K. Singhal, Stefan Michiels, Françoise Rothé, Roberto Salgado, Hugues Duvillier, Michail Ignatiadis, Christine Desmedt, Dominique Bron, Denis Larsimont, Martine Piccart, Christos Sotiriou, Karen Willard-Gallo

×

Figure 7

Genes predominately expressed in CD4+ TIL from extensively and minimally infiltrated tumors.

Options: View larger image (or click on image) Download as PowerPoint
Genes predominately expressed in CD4+ TIL from extensively and minimally...
(A) Heat map (red, upregulated; blue, downregulated) for a select group of differentially expressed genes in extensively compared with minimally infiltrated tumors (P1–P10 TIL; Supplemental Table 2G), including TCR/CD3 pathway, activation-induced, and conventional Th subset marker genes. Due to its high expression levels, the scale for CXCL13 is different. (B) CXCL13 transcript levels determined by qRT-PCR (normalized to TMBIM4 [endogen]) in either CD4+ or non-CD4 cells (remaining cells in CD4-depleted homogenates) from tumors and normal breast tissue (n = 6; 3 extensive [orange], 3 minimal [blue]; fold changes were normalized to the 3 minimal CD4+ cells). P values were calculated for several comparisons (Supplemental Table 5E), with the P value for CD4+ TIL (Ext vs. Min) shown (mean ± SEM). (C) CD14+ (monocyte), CD4+, remaining CD45+ (other leukocytes), and EpCAM+ cells (epithelial marker on breast tumor cells) were isolated from a minimally (TIL070) and an extensively infiltrated (TIL069) tumor. Expression of select cytokine/chemokine genes analyzed by qRT-PCR (red, high expression/low ΔCt; blue, low expression/high ΔCt; normalized to SDHA, TBP, and TMBIM4 as endogens).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts